Exelixis
EXEL
#1701
Rank
S$13.22 B
Marketcap
$46.30
Share price
0.62%
Change (1 day)
45.70%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Operating Margin for Exelixis (EXEL)

Operating Margin as of December 2024 (TTM): 28.81%

According to Exelixis's latest financial reports and stock price the company's current Operating Margin is 28.81%. At the end of 2023 the company had an Operating Margin of 14.07%.

Operating Margin history for Exelixis from 2001 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
202314.07%-3.27%
202214.55%-29.04%
202120.50%54.72%
202013.25%-67.79%
201941.14%-22.31%
201852.95%51.08%
201735.05%-195.55%
2016-36.68%-91.57%
2015-434.98%-58.23%
2014-1,041.29%33.27%
2013-781.34%151.29%
2012-310.93%-1269.7%
201126.58%-153.23%
2010-49.93%-46.19%
2009-92.81%-37.7%
2008-148.97%-12.86%
2007-170.96%33.08%
2006-128.46%2.92%
2005-124.81%-51.93%
2004-259.65%40.69%
2003-184.55%-3.24%
2002-190.73%13.94%
2001-167.39%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
10.36%-64.04%๐Ÿ‡ฌ๐Ÿ‡ง UK
15.40%-46.55%๐Ÿ‡ซ๐Ÿ‡ท France
3.14%-89.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-14.50%-150.33%๐Ÿ‡บ๐Ÿ‡ธ USA
14.38%-50.09%๐Ÿ‡บ๐Ÿ‡ธ USA
17.68%-38.63%๐Ÿ‡บ๐Ÿ‡ธ USA
1.80%-93.75%๐Ÿ‡บ๐Ÿ‡ธ USA
-473.04%-1,741.93%๐Ÿ‡บ๐Ÿ‡ธ USA
-30.78%-206.84%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.